US/UK/Canada

Share

Contacts

  • Immunovia AB
    Medicon Village Scheelevägen 8 SE-223 63 Lund
    +46 46 275 60 00
    http://www.immunovia.com
    • Pick a time period -
    Tags ( Active)

    Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.   The move to Research Triangle Park follows Immunovia’s successful model development study, announced on April 22, 2024 , and the successful

    Immunovia Publishes Interim Report for January-March 2024

    January-March 2024 · Net sales, which for the quarter only included royalties, amounted to SEK 156 (520) · Net earnings amounted to KSEK -2,946 (-51,658), where exchange rate effects of KSEK 21 358 (435) had a substantial impact. · Earnings per share before and after dilution were SEK -0.07 (-2.28). · Cash Flow from operating activities amount MSEK -24.4 (39.7). · Cash and equivalents at the end of the period amounted to MSEK 51.2 (68.2). · On January 31, the Company announced that Norma Alonzo Palma had been appointed Vice President of Clinical and Medical Affairs

    Invitation to Immunovia’s Q4 presentation

    LUND (SWEDEN) – Immunovia will publish its full year 2023 results on February 21, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and webcast Call any

    Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs

    LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, today announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.    As announced in July 2023, Immunovia significantly restructured to focus its resources on the company’s next-generation blood test for early detection of pancreatic cancer. After Immunovia successfully completed the discovery phase of the new test in November 2023, Norma’s appointment will enable Immunovia to

    Immunovia Publishes Interim Report for January-September 2023

    July-September 2023 · Net sales amounted to KSEK 488 (358) divided by sales of tests KSEK 70 (111) and royalties KSEK 418 (247). · Net earnings were MSEK -38.6 (-22.9) and earnings per share before and after dilution were SEK -0.91 (1.01). · Cash Flow from operating activities amount to MSEK -35 (-37). · Cash and equivalents at the end of the period amounted to MSEK 107 (159). · On July 11, the Company announced that it will cease commercialization of IMMray™ PanCan-d test in the United States to focus its resources on development of the next-generation pancreatic cancer

    Immunovia successfully completes discovery phase of next-generation test development

    LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced the successful completion of the discovery phase for the Company’s next-generation test.     The discovery study, which marks a key milestone in the development of Immunovia’s next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients.  The study is the most comprehensive pancreatic

    Nomination Committee appointed for Immunovia AB (Publ)

    LUND, SWEDEN – According to the instructions for the Nomination Committee of Immunovia AB (Publ) that were adopted at the Annual General Meeting on May 26, 2023, the Nomination Committee shall consist of four members.    The Nomination Committee, which is to be appointed for the period until a new Nomination Committee is appointed, shall consist of four members, of which three will be appointed by the Company's three largest shareholders in terms of voting, and the fourth shall be the Chair of the Board of Directors. If the Chair of the Board of Directors is one of the three largest

    Chief Executive Officer, Jeff Borcherding, buys Immunovia shares

    LUND (SWEDEN) – Immunovia AB (Nasdaq: IMMNOV) announces today that Jeff Borcherding, CEO of Immunovia, has purchased 350 000 shares for approximately 670 KSEK.His total holding now amounts to 350 000 shares and 100 000 warrants in Immunovia.       For more information, please contact:Karin Almqvist LiwendahlCFOkain.almqvist.liwendahl@immunovia.com+46 70 911 56 08     About ImmunoviaImmunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.    Our first product, IMMray™

    Bulletin from the Annual General Meeting in Immunovia AB

    LUND (SWEDEN) – On 26th May 2023, an Annual General Meeting (AGM) was held in Immunovia AB (publ), 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund. Below is a summary of the resolutions made at the AGM. Allocation of the company’s available profits and discharge from liability The AGM resolved that the company’s available profits, SEK 127,985,141, shall be brought forward and that no dividend shall be made. The board of directors and the managing directors were discharged from liability for the financial year 2022. Fees for the board and the auditor The AGM

    Immunovia Publishes Interim Report for January-March 2023

    January-March 2023 · Net sales amounted to kSEK 520 (182) divided by sales of tests kSEK 379 (122) and royalties kSEK 141(60). · Net earnings were MSEK -51.7 (-44.1) and earnings per share before and after dilution were SEK -2.28 (-1.95). · Cash Flow from operating activities were MSEK -39.7 (-46.1). · Cash and equivalents at the end of the period amounted to MSEK 68.2 (239.8). · On January 17, the Company appointed Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs · On January 19, the Company announced that a process to re-align the Swedish operations

    Changes to the Nomination Committee's proposal to the Annual General Meeting 2023 in Immunovia AB (publ)

    LUND (SWEDEN) – Immunovia AB (publ) ("Immunovia") published the notice to the Annual General Meeting 2023 on 25 April 2023 together with the Nomination Committee's motivated statement which included the Nomination Committee’s proposals for board members. The Nomination Committee has now been informed that Helge Lubenow, Sven Andréasson and Vanessa Rollings will not stand for election as board members in Immunovia. In addition, Philipp von Hugo has previously resigned from the Board of Directors and is thus not available for re-election as a board member.    Against this background,

    Invitation to Immunovia’s Q1 presentation

    LUND (SWEDEN) – Immunovia will publish its first quarter 2023 results on May 23, 2023 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com   Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on Immunovia’s development. The presentation will be held in English and be followed by a Q&A session. You are welcome to join via webcast or phone, see details below.   Telephone numbers and webcast Call

    Consultation process with Swedish unions completed

    LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first test dedicated to the early detection of pancreatic cancer, today announced that the consultation process regarding realigning its Swedish operations, announced on 19 January 2023, has been completed.    Immunovia is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. Following the early experience from the research collaboration with Proteomedix that was initiated in

    Immunovia announces updated financial calendar for financial year 2023

    LUND (SWEDEN) – Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2023 and 2024.   February 23, 2023    Year-end report 2022April 25, 2023   Q1 2023August 23, 2023   Q2 2023November 9, 2023   Q3 2023February 21, 2024   Year-end report 2023   The Annual General Meeting will be held on April 26, 2023.   For more information, please contact:Karin Almqvist LiwendahlCFOkarin.almqvist.liwendahl@immunovia.com (kain.almqvist.

    Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray™ PanCan-d test in the US market

    LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first blood test dedicated to the early detection of pancreatic cancer, today announced that it has appointed Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs effective February 1, 2023.   Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics. Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State

    Immunovia strengthens US organization to continue commercialization of its novel IMMray™ PanCan-d test

    LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company that has launched the world’s first blood test dedicated to the early detection of pancreatic cancer, today announced that its U.S. subsidiary, Immunovia Inc., has appointed a new National Sales Director. Jon Hager starts in his position today and has an extensive track record as a top-performing sales leader at companies like Ethos Labs, Myriad Genetics and Pfizer. He has earned multiple sales awards and promotions for his results and brings a wealth of experience growing new products, including at Myriad

    Centers for Medicare & Medicaid Services finalizes its payment determination and sets a rate of $897 for Immunovia’s IMMray PanCan-d test

    LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV) today announced that the Centers for Medicare and Medicaid Services (CMS) has finalized their payment determination on a price of $897 for Immunovia’s IMMray PanCan-d test. The determined rate will be effective from 1st January 2023.  After a period of public comment CMS agreed with the recommendation made by the Clinical Diagnostic Laboratory Test (CDLT) Advisory Panel to crosswalk IMMray PanCan-d rate to code 81503, brand name OVA1, and set a price of $897 for Immunovia’s test.    “The CMS decision is a significant milestone

    Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants

    LUND (SWEDEN) – Immunovia AB (Nasdaq: IMMNOV) announces today that Philipp Mathieu, CEO of Immunovia, has purchased 150000 warrants of the 2022/2026 scheme for approximately 297 KSEK.  His total holding now amounts to 2108 shares and 250 000 warrants in Immunovia. The warrants have a subscription price per share of SEK 88.69. Other management team members have subscribed for 100 000 warrants of the same scheme.     For more information, please contact:Karin Almqvist Liwendahl CFOkain.almqvist.liwendahl@immunovia.com+46 70 911 56 08       About Immunovia

    Immunovia announces the financial calendar for financial year 2023

    LUND (SWEDEN) – Immunovia, a diagnostic company with the vision to revolutionize blood-based diagnostics and survival rates for patients with cancer, announces its financial calendar for 2023 and 2024. February 9, 2023 Year-end report 2022April 25, 2023 Q1 2023August 24, 2023 Q2 2023November 9, 2023 Q3 2023February 21, 2024 Year-end report 2023 The Annual General Meeting will be held on April 27, 2023. For more information, please contact:Karin Almqvist LiwendahlCFOkain.almqvist.liwendahl@immunovia.com+46 70 911 56 08   About Immunovia Immunovia

    Immunovia Publishes Interim Report Jan-Sep 2022

    July-September 2022 · Net sales amount KSEK 358 (377) divided by sales of tests KSEK 111 and royalties KSEK 247. · Net earnings amount MSEK -23 (-36) and earnings per share before and after dilution were SEK – 1.01 (-1.60) · Cash Flow from operating activities amount MSEK -37 (-38). · Cash and equivalents at the end of the period amounted to MSEK 159 (339). · On July 5 the Company informed that a CPT PLA Code for the IMMray™ PanCan-d test was approved from the American Medical Association (AMA). The code will be effective from October 1, 2022. · On August 11 the Company

    Immunovia’s CEO to step down during 2022

    LUND, SWEDEN ― Immunovia AB (publ.) announced today that the Company’s President and Chief Executive Officer, Patrik Dahlen, has informed the Board of Directors of his intention to step down, for personal reasons. The search for a new CEO will start immediately. Although Patrik Dahlen will remain with the company for another six months to ensure an orderly transition, the Board would like to take this opportunity to express their gratitude already now for Patrik’s many contributions to the company.   Carl Borrebaeck, chairman of the Board of Directors, says:   “Immunovia’s

    The US based Pancreatic Cancer Action Network informs their members about Immunovia’s blood test IMMray™ PanCan-d

    LUND, SWEDEN –Immunovia AB (publ) (“Immunovia”), a diagnostic company that develops and sells highly accurate blood tests for the early detection of cancer, today announced that the largest patient organization for pancreatic cancer in the US – Pancreatic Cancer Action Network (PanCAN) – informed their constituents about Immunovia, Inc.’s blood test IMMray™ PanCan-d on its website, in social media and through direct email contact. PanCAN underlines  that IMMray™ PanCan-d is the first-ever blood test specific for

    Immunovia Publishes Report for the Second Quarter 2021

    LUND (SWEDEN) – Immunovia AB (publ) (“Immunovia”) has today published its report for the second quarter 2021. It is available on Immunovia’s website.  Patrik Dahlen, CEO: “We started the quarter by applying for a Massachusetts State License and CLIA Certification of the Immunovia, Inc. laboratory in Marlborough. After the period we received final approval to start patient testing with IMMray™ PanCan-d in the US. We are now very pleased to have received the final approval of our laboratory and that we now can launch the IMMray™ PanCan-

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media